Navigate this market better. Subscribe for FREE stock alerts and information.

Thursday, November 6, 2014

Allergan in discussions with another party after approach, (NYSE: AGN), (NYSE: VRX), (TSE: VRX.TO)

Allergan Inc on Thursday said that it is currently in discussions with another party that a source familiar with the situation identified as Actavis Inc, just days after the company disclosed that it had been approached. The discussions about a potential merger transaction could lead to "negotiations," Allergan said in a regulatory filing with the Securities and Exchange Commission related to its Dec. 18 meeting with shareholders.Allergan is fighting a $54 billion hostile takeover by Valeant Pharmaceuticals International and Pershing Square Capital Management, saying that Allergan's growth will be diminished and that Valeant will cut costs too deeply.Allergan had been holding off on talks with Actavis because it was waiting for a California judge to decide on its request for an injunction to stop William Ackman, head of Pershing Square, from voting at the shareholder meeting, a second source familiar with the situation previously told Reuters. The judge cleared the path for Ackman to vote his shares earlier this week by ordering Valeant and Pershing to add disclosures to their proxy filing, which the companies said they would.

Allergan, Inc. is a multi-specialty health care Company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products. Shares of AGN traded higher by 0.71% or $1.39/share to $197.71. In the past year, the shares have traded as low as $88.34 and as high as $196.54. On average, 2343280 shares of AGN exchange hands on a given day and today's volume is recorded at 610690.

Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX fell by 0.39% or $-0.51/share to $131.40. In the past year, the shares have traded as low as $102.93 and as high as $153.10. On average, 2634030 shares of VRX exchange hands on a given day and today's volume is recorded at 359894.

Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX fell by 0.08% or $-0.12/share to $149.93. In the past year, the shares have traded as low as $107.74 and as high as $170.45. On average, 474655 shares of VRX.TO exchange hands on a given day and today's volume is recorded at 27644.



Source